All In Biotech

Drug Trial Radar · NCT06958861

A Clinical Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Inhaled H057 in the Treatment of Acute Exacerbations of Bronchiectasis

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Inhaled H057 in the Treatment of Acute Exacerbations of Bronchiectasis

Last checked: Nov 20, 2026Latest source record: May 9, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 180 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

180

Planned (sponsor's estimate)

Start

May 2025

Primary completion

May 2027

Study completion May 2027

Sponsor

Sponsor type
Industry
First posted
May 6, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, randomized, double-blind, placebo-controlled trial to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of inhaled H057 in the treatment of acute exacerbations of bronchiectasis.

Conditions

  • Acute Exacerbations of Bronchiectasis

Interventions

  • Low-dose H057+standard-of-careDrug

    Subjects are administered low-dose inhaled H057, combined with standard-of-care treatment, which included anti-infective therapy, expectorant therapy, hemostasis, oxygen therapy, and other supportive measures.

  • High-dose H057+standard-of-careDrug

    Subjects are administered high-dose inhaled H057, combined with standard-of-care treatment, which included anti-infective therapy, expectorant therapy, hemostasis, oxygen therapy, and other supportive measures.

  • H057 placebo+standard-of-careDrug

    Subjects are administered inhaled H057 placebo, combined with standard-of-care treatment, which included anti-infective therapy, expectorant therapy, hemostasis, oxygen therapy, and other supportive measures.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Quality-of-Life Bronchiectasis Respiratory Symptom ScoreTime frame: baseline to day 15

Locations

19 sites in 1 country. Site status is shown where the registry gives one.

  • Fuyang Hospital Of Anhui Medical University

    Fuyang, Anhui, China

  • Hefei First People's Hospital

    Hefei, Anhui, China

  • Fujian Medical University Union Hospital

    Fuzhou, Fujian, China

  • The First Affiliated Hospital of Guangzhou Medical University

    Guangzhou, Guangdong, China

  • Peking University Shenzhen Hospital

    Shenzhen, Guangdong, China

  • Affiliated hospital of Youjiang Medical University For Nationalities

    Baise City, Guangxi, China

  • Hebei General Hospital

    Shijiazhuang, Hebei, China

  • Nanyang Second General Hospital

    Nanyang, Henan, China

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, China

  • Yichang Central People's Hospital

    Yichang, Hubei, China

  • The second Xiangya Hospital of Central South University

    Changsha, Hunan, China

  • Changzhou First People's Hospital

    Changzhou, Jiangsu, China

  • Jiujiang No.1 People's Hospital

    Jiujiang, Jiangxi, China

  • Sichuan Provincial People's Hospital

    Chengdu, Sichuan, China

  • Deyang People's Hospital

    Deyang, Sichuan, China

  • Hangzhou First People's Hospital

    Hangzhou, Zhejiang, China

  • Jinhua Municipal Central Hospital

    Jinhua, Zhejiang, China

  • Ningbo No.2 Hospital

    Ningbo, Zhejiang, China

  • The First Affiliated Hospital of Wenzhou Medical University

    Wenzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.